MEX3C as a potential target for hepatocellular carcinoma drug and immunity: combined therapy with Lenvatinib.

ABSTRACT:

Background

The immune microenvironment within hepatocellular carcinoma (HCC) is remarkably intricate. Although the combination of an immune checkpoint inhibitor and Lenvatinib can extend the overall survival of HCC patients, the outcome remains suboptimal.

Methods

We assessed alterations in MEX3C expression during hepatocarcinogenesis by validating multiple databases and subsequently developed a predictive model. Subsequently, we enriched the associated genes of MEX3C to investigate its functional role. We examined the correlation between MEX3C expression levels and immune infiltrating cells. The effects of MEX3C knockdown and Lenvatinib on hepatoma cells were observed by cell function experiments.

Results

MEX3C expression is elevated in HCC compared to normal tissues

SUBMITTER: Guo J 

PROVIDER: S-EPMC10568896 | biostudies-literature | 2023 Oct

REPOSITORIES: biostudies-literature